Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.51 |
| ▸ | CTSL | P07711 | 6/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31567153 | 0.84 | TSHR (0.42) | CTSSCTSLCTSKCTSBTSHR | |
| SCHEMBL9852800 | 0.83 | TSHR (0.45) | CTSSCTSLCTSKCTSBTSHR | |
| SCHEMBL9751568 | 0.83 | TSHR (0.45) | CTSSCTSLCTSKCTSBTSHR | |
| SCHEMBL3033151 | 0.80 | CTSS (0.61) | CTSSCTSLCTSKCTSB | |
| SCHEMBL4505588 | 0.80 | CTSS (0.60) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3027455 | 0.78 | CTSS (0.68) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3028847 | 0.78 | CTSS (0.58) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3648827 | 0.77 | TSHR (0.50) | CTSSCTSLCTSKTSHRCA1 | |
| SCHEMBL25055443 | 0.77 | CTSC (0.54) | CTSSCTSLCTSK | |
| SCHEMBL7512123 | 0.77 | CTSC (0.54) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101553474-B | Imidazolidinone and imidazolidinone derivatives as 11b-HSD1 inhibitors for diabetes | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| CN-101553474-A | Imidazolidinone and imidazolidinone derivatives as 11 b-HSD 1 inhibitors for diabetes | HOFFMANN LA ROCHE (CH) | 2009-10-07 | — | — | CN | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | CTSS 3983/4885CTSL 4222/4885CTSK 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.